JPMorgan Chase & Co. Acquires 124,246 Shares of Illumina, Inc. $ILMN

JPMorgan Chase & Co. grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 17.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 832,690 shares of the life sciences company’s stock after buying an additional 124,246 shares during the period. JPMorgan Chase & Co. owned 0.54% of Illumina worth $79,081,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Generali Asset Management SPA SGR boosted its holdings in shares of Illumina by 51.6% during the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after buying an additional 7,574 shares during the period. Aaron Wealth Advisors LLC grew its stake in Illumina by 342.6% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock valued at $995,000 after buying an additional 8,109 shares during the last quarter. Elo Mutual Pension Insurance Co bought a new position in Illumina in the 3rd quarter valued at about $2,319,000. Douglas Lane & Associates LLC raised its holdings in Illumina by 6.6% in the 3rd quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock valued at $29,214,000 after acquiring an additional 18,914 shares during the period. Finally, Nordea Investment Management AB lifted its position in Illumina by 148.6% during the third quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company’s stock worth $3,024,000 after acquiring an additional 19,519 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $122.95 on Thursday. The company’s 50 day moving average price is $131.64 and its two-hundred day moving average price is $120.41. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53. The firm has a market cap of $18.80 billion, a PE ratio of 22.56, a PEG ratio of 2.31 and a beta of 1.45. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insiders Place Their Bets

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ILMN has been the subject of a number of research analyst reports. Robert W. Baird set a $137.00 price objective on Illumina in a report on Friday, February 6th. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Canaccord Genuity Group boosted their price target on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, January 26th. Piper Sandler reduced their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Finally, Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Illumina has a consensus rating of “Hold” and an average target price of $129.69.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.